** Shares of biotech co NeuBase Therapeutics rise ~4% to 62 cents, set to snap 6-day losing streak
** Co says it terminated CEO Dietrich Stephan without cause and appointed CFO Todd Branning to the post
** Branning has been serving as the company's finance chief since January 2022 and will continue in this role during his tenure as the interim CEO
** Since Stephan took over as CEO in 2019, co's stock has lost almost all its value; In the last 12 months, it has fallen 89.3%
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments